Avatrombopag is used to treat thrombocytopenia, a condition characterized by low platelet count, in adults with chronic liver disease who are scheduled to undergo a medical procedure. It helps increase platelet levels, reducing the need for platelet transfusions and lowering the risk of bleeding during surgeries or invasive procedures. The drug works by stimulating the thrombopoietin receptor, which promotes the production of platelets in the bone marrow. It is taken orally, making it a convenient option for patients prior to planned interventions.